<DOC>
	<DOCNO>NCT02908490</DOCNO>
	<brief_summary>The purpose study determine whether sildenafil improve parameter vascular function blood marker involve development heart disease patient rheumatoid arthritis .</brief_summary>
	<brief_title>Does Sildenafil Improve Endothelial Dysfunction Rheumatoid Arthritis ?</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) associate 2-fold increase risk cardiovascular disease ( CVD ) , explain traditional cardiovascular ( CV ) risk factor alone ; risk likely mediate part systemic inflammation . Indeed , RA deem impart CV risk equivalent diabetes mellitus ( DM ) . However , unlike DM , optimal CV management strategy RA lack . Despite improved anti-inflammatory therapy RA , mortality gap RA compare general population still widen , part due suboptimal primary secondary CV preventive care RA . To date , publish control intervention trial primary CV prevention RA , despite clearly urgent unmet need . One early stage atherogenesis endothelial dysfunction , drug target improvement promising novel strategy CVD prevention . The fundamental feature endothelial dysfunction impair nitric oxide ( NO ) bioavailability . Sildenafil improve endothelial function increase NO signal inhibition phosphodiesterase-5 ( PDE5 ) . PDE5 inhibitor improve endothelial function pulmonary hypertension DM , safe well tolerated patient erectile dysfunction CV comorbidities . Furthermore , PDE inhibitor immunomodulatory property may utilize treat autoimmune condition like RA . The investigator ' central hypothesis sildenafil uniquely suit agent target endothelial dysfunction novel adjunctive CV prevention strategy immunomodulatory agent RA . Specifically , goal determine sildenafil use RA improve endothelial dysfunction atherosclerosis biomarkers . The propose study phase II , randomize double-blind placebo-controlled crossover efficacy trial 60 RA patient , know history CVD least one traditional CV risk factor , stable baseline dos RA medication ; randomize 1:1 receive either sildenafil 50 mg placebo orally daily 3 month , 2-week washout crossover phase another 3 month . Vascular study validate assess endothelial dysfunction laboratory study select atherosclerosis biomarkers perform baseline , 3 month pre- post-washout , 6 month . Adverse event collect assess safety . The Specific Aims : 1 . To determine whether sildenafil use RA lead improvement parameter vascular function ; confirm safety profile . 2 . To determine whether sildenafil use RA associate improvement atherosclerosis biomarkers . The result study serve preliminary data future large trial evaluate sildenafil CV prevention strategy reduce endothelial dysfunction RA . It provide need data potential benefit sildenafil immunomodulation CV prevention high-risk population .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Meets 2010 American College Rheumatology ( ACR ) classification criterion diagnosis RA Aged 18 year old No known history CVD ( see Exclusion Criteria ) At least one traditional CV risk factor ( i.e. , old age [ men ≥45 year , woman ≥55 year ] , obesity [ define body mass index ( BMI ) &gt; 30 kg/m2 ] , smoking , hypertension , hyperlipidemia , diabetes mellitus , family history premature [ define diagnosed &lt; 65 year old ] CVD firstdegree relative ) On stable baseline dos RA medication , define change dose within past 12 week anticipate change next 6 month On high 10 mg per day prednisone prednisoneequivalent within past 12 week RA disease duration ( symptom onset ) 6 month , less 10 year Having clinical disease activity index ( CDAI ) &gt; 2.8 ≤22 ( i.e. , either low moderate disease activity ) , within 30 day study enrollment Aged &lt; 18 year Pregnant woman Known personal history CVD ( clinical diagnosis stroke , transient ischemic attack , myocardial infarction , acute coronary syndrome , peripheral arterial disease , percutaneous coronary intervention coronary bypass graft surgery ) Use statins blood pressure medication may affect endothelial function ( i.e. , angiotensinconvertingenzyme [ ACE ] inhibitor angiotensin receptor blocker [ ARBs ] ) currently within past 3 month Persons intracardiac intrapulmonary shunt , unstable cardiopulmonary condition , anyone chronic oxygen therapy Persons take nitric oxide donor , organic nitrite nitrate , glyceryl trinitrate ( nitroglycerin ) , sodium nitroprusside , amyl nitrite ( `` popper '' ) Severe hepatic impairment ( liver function test &gt; 1.5 time upper limit normal ) within past 3 month Severe impairment renal function ( serum creatinine ≥1.5 mg/dL ) within past 3 month Hypotension ( define blood pressure [ BP ] &lt; 90/60 ) Hereditary degenerative retinal disorder ( include genetic disorder retinal phosphodiesterases ) Persons already take ( take within 3 month ) sildenafil PDE inhibitor ( i.e. , tadalafil , vardenafil ) Persons unable provide voluntary write informed consent Severe hypertension ( BP &gt; 170/110 ) Persons HIV/AIDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>